{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:46:44Z","timestamp":1773118004797,"version":"3.50.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key Projects of Natural Science Foundation Program for Universities in Anhui Province","award":["2024AH051032"],"award-info":[{"award-number":["2024AH051032"]}]},{"name":"Scientific Research Project on TCM Inheritance and Innovation in Anhui Province","award":["2024CCCX001"],"award-info":[{"award-number":["2024CCCX001"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973825"],"award-info":[{"award-number":["81973825"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Penicillamine(D-Penicillamine) and trientine are first-line therapies for Wilson\u2019s Disease (WD), yet real-world data on their adverse events (AEs) remain scarce. We analyzed the FDA Adverse Event Reporting System (FAERS) to comprehensively assess the safety of penicillamine and trientine in WD treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AEs for penicillamine and trientine (2004Q1\u20132024Q4) were analyzed using Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Bayesian Confidence Propagation Neural Network (BCPNN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found 1,452 and 760 AEs related to penicillamine and trientine, respectively. In all adverse event (AE) reports, the ratio of females to males was approximately 1.3, with the highest proportion of AE reports in the 21\u201330 age group, and the largest number of AE reports coming from the United States. Signal detection showed that the most commonly reported AEs for penicillamine and trientine were drug hypersensitivity and tremor, respectively, with the highest proportions in the SOC categories of immune system disorders and gastrointestinal disorders. The main AEs for both drugs involved condition aggravated, and identified potential safety signals requiring further validation for the two drugs, such as decreased bone density and brain atrophy for penicillamine, and memory impairment, oesophageal ulcer and starvation for trientine. In addition, we found that women were more likely to experience drug hypersensitivity in penicillamine adverse event reports, while men were more likely to experience cutis laxa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study reveals the characteristics of AEs and potential associated risks in the clinical application of penicillamine and trientine, emphasizing individualized medication and vigilant monitoring strategies to provide guidance for safe medication use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0336721","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:29:36Z","timestamp":1762972176000},"page":"e0336721","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of penicillamine and trientine in the treatment of Wilson\u2019s disease: An analysis of the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1371","volume":"20","author":[{"given":"Wenlong","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjie","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2004-4358","authenticated-orcid":true,"given":"Yonghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"9559","key":"pone.0336721.ref001","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(07)60196-2","article-title":"Wilson\u2019s disease","volume":"369","author":"A Ala","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"pone.0336721.ref002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41572-018-0018-3","article-title":"Wilson disease","volume":"4","author":"A Cz\u0142onkowska","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"pone.0336721.ref003","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/hep.22261","article-title":"Diagnosis and treatment of Wilson disease: an update","volume":"47","author":"American Association for Study of Liver Diseases (AASLD)","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"pone.0336721.ref004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1474-4422(14)70190-5","article-title":"Wilson\u2019s disease and other neurological copper disorders","volume":"14","author":"O Bandmann","year":"2015","journal-title":"Lancet Neurol"},{"issue":"4","key":"pone.0336721.ref005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0002-9343(56)90066-3","article-title":"Penicillamine, a new oral therapy for Wilson\u2019s disease","volume":"21","author":"JM Walshe","year":"1956","journal-title":"Am J Med"},{"issue":"24","key":"pone.0336721.ref006","first-page":"02706","article-title":"EASL-ERN Clinical Practice Guidelines on Wilson\u2019s disease","author":"European Association for the Study of the Liver","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"pone.0336721.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2013.03.012","article-title":"Efficacy and safety of oral chelators in treatment of patients with Wilson disease","volume":"11","author":"KH Weiss","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"pone.0336721.ref008","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-024-02099-0","article-title":"Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review","volume":"84","author":"COF Kamlin","year":"2024","journal-title":"Drugs"},{"issue":"9565","key":"pone.0336721.ref009","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(07)60438-3","article-title":"Wilson\u2019s disease","volume":"369","author":"JM Walshe","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"pone.0336721.ref010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4254\/wjh.v14.i8.1687","article-title":"Hemorrhagic colitis induced by trientine in a 51-year-old patient with Wilson\u2019s disease waiting for liver transplantation: A case report","volume":"14","author":"A Schult","year":"2022","journal-title":"World J Hepatol"},{"issue":"4","key":"pone.0336721.ref011","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jocn.2012.02.041","article-title":"Trientine-induced neurological deterioration in a patient with Wilson\u2019s disease","volume":"20","author":"B Kim","year":"2013","journal-title":"J Clin Neurosci"},{"issue":"1","key":"pone.0336721.ref012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MPG.0000000000002902","article-title":"Optimized Trientine-dihydrochloride Therapy in Pediatric Patients With Wilson Disease: Is Weight-based Dosing Justified?","volume":"72","author":"T Mayr","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"pone.0336721.ref013","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jamia\/ocv153","article-title":"OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data","volume":"23","author":"TA Kass-Hout","year":"2016","journal-title":"J Am Med Inform Assoc"},{"issue":"11","key":"pone.0336721.ref014","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/14740338.2021.1956460","article-title":"Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system","volume":"20","author":"V Kumar","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"pone.0336721.ref015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S2468-1253(22)00270-9","article-title":"Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"ML Schilsky","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"pone.0336721.ref016","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneur.60.3.379","article-title":"Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy","volume":"60","author":"GJ Brewer","year":"2003","journal-title":"Arch Neurol"},{"key":"pone.0336721.ref017","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"C Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"pone.0336721.ref018","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system","volume":"73","author":"L Meng","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"9","key":"pone.0336721.ref019","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring Novel Adverse Events of Nefecon","volume":"9","author":"J Wang","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"1","key":"pone.0336721.ref020","doi-asserted-by":"crossref","first-page":"2461668","DOI":"10.1080\/0886022X.2025.2461668","article-title":"Real-world assessment of sparsentan\u2019s drug safety framework","volume":"47","author":"W Fu","year":"2025","journal-title":"Ren Fail"},{"issue":"6","key":"pone.0336721.ref021","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"pone.0336721.ref022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems","volume":"37","author":"Y Noguchi","year":"2020","journal-title":"Pharm Res"},{"issue":"1","key":"pone.0336721.ref023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"13","key":"pone.0336721.ref024","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/sim.3586","article-title":"Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting","volume":"28","author":"I Ahmed","year":"2009","journal-title":"Stat Med"},{"key":"pone.0336721.ref025","doi-asserted-by":"crossref","first-page":"990241","DOI":"10.3389\/fphar.2022.990241","article-title":"Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0336721.ref026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"I Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"9","key":"pone.0336721.ref027","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/tx900128p","article-title":"D-penicillamine-induced autoimmunity: relationship to macrophage activation","volume":"22","author":"J Li","year":"2009","journal-title":"Chem Res Toxicol"},{"issue":"7","key":"pone.0336721.ref028","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1021\/tx900087z","article-title":"Covalent binding of penicillamine to macrophages: implications for penicillamine-induced autoimmunity","volume":"22","author":"J Li","year":"2009","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"pone.0336721.ref029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.autrev.2005.01.002","article-title":"Current trends in drug-induced autoimmunity","volume":"4","author":"J Uetrecht","year":"2005","journal-title":"Autoimmun Rev"},{"issue":"12","key":"pone.0336721.ref030","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.dld.2019.08.025","article-title":"D-penicillamine-induced autoimmune disorders","volume":"51","author":"T Rozina","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"7","key":"pone.0336721.ref031","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jamadermatol.2013.8635","article-title":"Elastosis perforans serpiginosa: a case of a penicillamine-induced degenerative dermatosis","volume":"150","author":"S Hellriegel","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"1","key":"pone.0336721.ref032","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/abbi.1994.1042","article-title":"Regulation of lysyl oxidase mRNA in dermal fibroblasts from normal donors and patients with inherited connective tissue disorders","volume":"308","author":"HN Yeowell","year":"1994","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"pone.0336721.ref033","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2008.09.018","article-title":"Penicillamine-induced elastosis of the mucosal lip","volume":"60","author":"BKH Lewis","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0336721.ref034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/tera.1420330116","article-title":"Teratogen update: penicillamine","volume":"33","author":"FW Rosa","year":"1986","journal-title":"Teratology"},{"issue":"1","key":"pone.0336721.ref035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jns.2003.08.007","article-title":"Successful pregnancies and abortions in symptomatic and asymptomatic Wilson\u2019s disease","volume":"217","author":"S Sinha","year":"2004","journal-title":"J Neurol Sci"},{"key":"pone.0336721.ref036","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.reprotox.2016.06.015","article-title":"Pregnancy outcome after chelation therapy in Wilson disease. Evaluation of the German Embryotox Database","volume":"65","author":"K Dathe","year":"2016","journal-title":"Reprod Toxicol"},{"issue":"1","key":"pone.0336721.ref037","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","article-title":"Copper homeostasis and cuproptosis in health and disease","volume":"7","author":"L Chen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"pone.0336721.ref038","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ene.12348","article-title":"D-penicillamine versus zinc sulfate as first-line therapy for Wilson\u2019s disease","volume":"21","author":"A Cz\u0142onkowska","year":"2014","journal-title":"Eur J Neurol"},{"issue":"2","key":"pone.0336721.ref039","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2023.04.007","article-title":"Neurological worsening in Wilson disease - clinical classification and outcome","volume":"79","author":"I Mohr","year":"2023","journal-title":"J Hepatol"},{"key":"pone.0336721.ref040","first-page":"359","article-title":"Copper: effects of deficiency and overload","volume":"13","author":"I Scheiber","year":"2013","journal-title":"Met Ions Life Sci"},{"issue":"4","key":"pone.0336721.ref041","doi-asserted-by":"crossref","first-page":"248","DOI":"10.5414\/CN111402","article-title":"Kidney complications of Wilson disease and its treatments: A case report and literature review","volume":"102","author":"M Salman","year":"2024","journal-title":"Clin Nephrol"},{"issue":"8","key":"pone.0336721.ref042","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/09513590.2010.507281","article-title":"Estrogen promotes B cell activation in vitro through down-regulating CD80 molecule expression","volume":"27","author":"Y Fu","year":"2011","journal-title":"Gynecol Endocrinol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:29:43Z","timestamp":1762972183000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336721"}},"subtitle":[],"editor":[{"given":"Jingyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0336721","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}